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EfficacyErythrodermic psoriasis (EP) is one of the most severe
cutaneous conditions which may lead to serious morbidity and
even mortality. This condition is often difficult to manage and, due
to its rarity (estimated prevalence 1–2.25% of psoriatic patients)
there is a lack of high-quality medical literature examining
treatment options [1].
Data on the use of biologics in EP are very sparse because
erythroderma represented exclusion criteria in all the main studies
investigating biologics efficacy and safety in psoriasis [1,2].Table 1
Baseline characteristics of the 22 studied patients.
Patients Sex Age Pso Age EP Previous treatment P
1 M 25 46 Cs, PUVA, ETA 
2 M 40 59 MTX, Cs, EFA, ETA 
3 F 13 53 Cs, MTX, EFA, ETA, IN
4 M 23 45 Cs, MTX 
5 M 46 46 – 
6 M 49 67 UVB, MTX 
7 F 35 67 – 
8 M 46 63 Cs 
9 M 57 62 Ret, MTX, Cs 
10 M 29 46 Ret, MTX, Cs 
11 M 29 36 Cs 
12 F 49 54 Cs, Ret, ADA 
13 F 15 15 – 
14 F 9 26 PUVA, MTX, Cs, EFA 
15 F 28 34 – 
16 F 12 42 Cs, PUVA 
17 M 23 43 Ret, PUVA 
18 M 9 54 Cs, PUVA 
19 M 29 34 Cs, Ret, ADA, ETA 
20 M 38 61 UVB, Cs, MTX, Ret 
21 M 56 66 UVB, MTX, Ret 
22 F 59 59 Cs, PUVA, Ret 
CCS: systemic corticosteroids; Cs: ciclosporin; Ret: oral retinoids; MTX: methotrexate
efalizumab; ETA: etanercept; INF: infliximab. Topical therapies not included.
0923-1811/ 2015 Japanese Society for Investigative Dermatology. Published by ElsevUntil now only two retrospective studies have tried to assess
the efficacy and safety of anti-TNF-a in EP with promising results
[3,4].
Here we report the results from a multicenter, retrospective
analysis of patients with EP treated with ustekinumab in 9 Italian
Dermatology Hospital Departments.
Data of 22 patients with EP (defined as a generalized,
inflammatory erythematous dermatosis, with or without associ-
ated exfoliation lasting for at least 3 months involving at least 75%
of the body surface area, with the characteristic clinical and/or
histological features of psoriasis and the exclusion of the other
main differential diagnoses for erythroderma) [1], treated with
ustekinumab between February 2010 and July 2014, were
included. Each patient has been evaluated with the Psoriasis Area
and Severity Index (PASI), before and after 4, 16 and 28 weeks of
treatment.
Baseline characteristics of the study population are summa-
rized in Table 1.
19 patients have a positive personal history of plaque type
psoriasis while 3 experienced erythroderma since the beginning of
the disease. In the latter cases diagnosis of EP was made excluding
other possible causes of erythroderma.
Patients received ustekinumab at weeks 0, 4 and then every
12 weeks. 16 patients (weighting 100 kg) received ustekinumab




F CCS 40 45
Ret, CCS 45 90
Cs, Ret, CCS 49 90
MTX, Cs, UVB 41 45
Cs, MTX, Ret, ADA 48 90
Cs, CCS, ADA 48.8 45
Ret, Cs, ADA, ETA 63 45
Ret, Cs, ETA 57.2 45
Cs, CCS 37.8 45
Cs, ETA, INF, CCS 45.2 45
MTX, Cs, Ret, CCS 35 45
ADA, ETA 42 90





INF, ADA, ETA 42 45
Cs, CCS 41 45
– 40.8 45
; PUVA: psoralen plus ultraviolet A; UVB: ultraviolet B; ADA: adalimumab; EFA:
ier Ireland Ltd. All rights reserved.
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onset of EP.
The remaining 17 patients received as first treatment for EP,
prior to ustekinumab, systemic steroids, conventional systemic
treatments (acitretin, methotrexate, cyclosporine) phototherapy,
other biologic therapies.
The efficacy of ustekinumab was assessed by the proportion of
patients reaching a 50, 75 and 90% improvement in PASI (PASI 50,
PASI 75, PASI 90) at different time points (Fig. 1).
After 4 weeks of ustekinumab treatment more than half of
patients showed a clinical improvement of at least 50% compared
with baseline PASI score while after 16 weeks about two third of
patients reached PASI75. After 28 weeks of treatment 68.2% of
patients reached PASI 90, 86.3% PASI 75 and 90.9% PASI 50.
At the time of data collection, the median follow-up duration
was 60 weeks (mean 66.5, range 24–120 weeks) after the onset of
ustekinumab treatment.
16 patients were still receiving ustekinumab with a median
PASI of 2.3 (mean 2, range 0–8) at the end of the follow-up period.
Causes of treatment withdrawal were failure in PASI 50 achieve-
ment after 28 weeks (2 patients) and clinical remission
(4 patients).
EP is one of the clinical subtypes of psoriasis associated with
poor prognosis and direct mortality [1].
EP most commonly arises from a pre-existing long-standing
chronic psoriasis vulgaris or, more rarely, it can occur abruptly as
the initial presentation of psoriasis.
Current evidence supporting the use of biologics in EP is limited
to case reports and case series [1].
To the best of our knowledge this is the largest retrospective
study investigating the efficacy and safety of ustekinumab in
patients with EP.
Successful use of ustekinumab in EP was reported in various
case reports [5–10] underlining its efficacy even after failure of
various anti-TNF agents.
The larger evaluation of ustekinumab in EP currently available
is an Asian case series of 8 patients with 75%, 50% and 37.5% of
patients reaching respectively PASI50, PASI75 and PASI90 at week
28 [10]. In this study ustekinumab 45 mg was given only at
baseline and after 4 weeks; this could explain their disappointing
results. Moreover, it seems that biologics treatment for psoriasisFig. 1. Improvement of PASI of the 22 stumay have a less impressive response in Asian races, as stated also
by the same authors. In a recent French multicenter retrospective
study on the safety and efficacy of different biologic treatments in
EP, 3 patients were treated with ustekinumab with only limited
efficacy reported [3]. However the authors underscored that in the
reported cases ustekinumab treatment was prescribed as a fourth-
line biological treatment in all cases, and these were the most
recalcitrant ones.
Our case series highlight the efficacy of ustekinumab in
EP with a percentage of patients reaching PASI 75 close to 70%
at week 16 weeks. This percentage increases more than 80%
at week 28. In terms of time related clinical improvement
(PASI reduction) our results are equal to or greater than those
obtained with others biologics [2,3]. The four patients who have
withdrawal ustekinumab after reaching clinical remission have
maintained this condition throughout the end of the follow-up
period.
Ustekinumab was generally well tolerated and patients were
compliant and satisfied.
No severe infection, injection site reaction, or drug-related
laboratory abnormalities have been reported among the subjects
enrolled in this study.
We didn’t find any relation among any clinical factors (BMI,
previous treatments, duration of EP, smoking habit) and quality of
response (efficacy, quick onset of response) to ustekinumab
treatment. This may be due to the limited number of patients of
our study.
Our retrospective analysis demonstrates that ustekinumab is a
highly effective treatment for EP, providing rapid and significant
clinical response associated with an excellent safety profile.
The limitation of the current study is that the efficacy of
ustekinumab was investigated retrospectively. Another limitation
should be the small number of patients included but talking about
EP treatment with one biologic this represents the longest series up
to now.
Even if there is a clear need for dedicated and prospective
comparative clinical trials to assess which are the safest and most
efficacious therapies for the management of EP, the rapidity of
clearance and the excellent safety profile observed in our case
series suggests that ustekinumab can play an important role in its
management.died patients at different timelines.
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Atopic dermatitis-like dermatitis emerges
unevenly on different sites in flaky tail miceFig. 1. Physiological and histological findings. Transepidermal water loss (TEWL, A),
stratum corneum (SC) pH (B), and epidermal thickness (C) were compared at each
site between old C57BL/6 (WT) and flaky tail mice (FTM) (40- to 90-week-old), as
described in the supplementary file. N = 7–9 in A, N = 5–8 in B, and N = 6–10 in C. NS,
not significant, * P < 0.05, ** P < 0.01.To the Editor,
Flaky tail mice (FTM; ma/ma, Flgft/ft) have two pathogenic
genetic abnormalities related to cutaneous permeability barrier
homeostasis, namely, gene mutations in filaggrin (Flgft) and
matted (ma), and are known to exhibit atopic dermatitis (AD)-
like dermatitis ‘‘spontaneously’’ and the spontaneous emergence
is mainly attributed to the matted mutation [1–4]. Although FTM
has been used as one of the murine AD models, whether such
spontaneous emergence is consistent with the pathogenesis of
human AD, in which genetic abnormalities are not the sole
determinant but the combination of genetic abnormalities and
environmental factors is the most important characteristic,
remains questionable. In the present study, we determined
whether site-dependent emergence of skin manifestations,
which is one of clinical characteristics of human AD, is seen in
FTM.
The severity of dermatitis and age of onset in FTM differ among
laboratories [1,2,5,6]. Such inconsistency might be related to the
presence or absence of the matted mutation and/or to variations in
the genetic background of individual strains and in environmental
factors [2,7]. In our laboratory, young FTM (7–8 weeks old) did nothave any clinical or histological symptoms of dermatitis [8]. FTM
aged over 40 weeks (old FTM) developed marked dermatitis on the
ears, eyelids, cheeks and neck accompanied by elevation of serum
IgE levels (Fig. 1, Supplementary Figs. S1–S3). The dermatitis on the
